Ardmore Shipping (ASC) Stock

The latest trading day saw Ardmore Shipping (ASC) settling at $11.99, representing a +0.17% change from its previous close.

Recently, Zacks.com users have been paying close attention to Ardmore Shipping (ASC). This makes it worthwhile to examine what the stock has in store.

Among the tanker companies I have researched so far, Ardmore Shipping is the only player exposed to the chemical market. Another important element that differentiates ASC from other tanker operators is its net cash balance, which represents ~5.0% of its current market capitalization. According to management, Ardmore would generate earnings per share of approximately $1.97 using charter rates of $25,000 per day, which is roughly in line with what was reported in Q3.

In a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg, subcutaneous ( SQ ) , once every four weeks plus semaglutide, 30 nmol/kg, SQ, once daily) ,  demonstrated superior weight loss compared to semaglutide monotherapy (30 nmol/kg, SQ, once daily), showing an average total body weight reduction of 36.2% compared to 23.1%, a 56.7% greater reduction in body weight compared to semaglutide monotherapy. Human equivalent dose of ASC47 low dose 1 (3 mg/kg, SQ, once every four weeks) in mice is estimated to be approximately 20 mg based on the body surface area conversion.

Ardmore Shipping (ASC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

The third quarter results were not that bad. Compared to 3Q23, Ardmore realized higher revenue, EBITDA, and EPS. According to the company's estimates, an additional $10,000 per day equals an annual increase of about $2.25 in EPS increase and nearly $100 million in FCF growth. As of November 06, Ardmore holds $47.6 million cash and owes $30.0 million total debt. Its Total Debt-to-Equity ratio is 8.1%.

Ardmore Shipping's strategic advantage lies in its eco-friendly fleet and operational flexibility, enabling it to capitalize on shifting market dynamics between chemical and petroleum products. Q3 results showed double-digit growth in revenue and EPS, along with improved TCE rates and record-low breakeven levels. Ardmore's balance sheet has strengthened, reducing debt from $97 million to $23 million, and rewarding shareholders with consecutive dividend payouts.

-Phase III trial enrolled a total of 480 patients with moderate to severe acne -Topline results expected in the second quarter 2025 HANGZHOU, China , Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat) o nce-daily oral tablet for treatment of moderate to severe acne. The first patient was enrolled on January 24, 2024.